Enzyme saturation in biosensing has been established as a main hindrance in lactate monitoring due to the high concentration of this species in biological samples. In this paper, a Sonogel–carbon transducer has been used for the fabrication of an amperometric biosensor for lactate (LA) determination. The sensor was constructed by immobilizing lactate oxidase as the bioreceptor and coating the electrode surface with multipolymer layers to minimize enzyme saturation and improve operational stability. This biosensor shows adequate sensitivity (1.74 µA mM − 1 cm -2 ) in a linear working range from 0.2 mM to 20 mM, suitable for physiological lactate concentrations in biofluids. The response of the biosensor was studied in physiological medium using several potential interferents (glucose, uric acid, dopamine, ascorbic acid, KCl, NaCl, CaCl 2 and BSA), demonstrating negligible interference from these common electroactive species. A microfluidic cell was designed and fabricated using polyethylene terephthalate glycol (PETG) through a rapid and low-cost 3D printing process. Finally, the prepared microfluidic cell was applied to lactate monitoring in flow regime using the biosensor with both synthetic and real untreated human serum samples, showing excellent correlation with two standard reference techniques and confirming its reliability. These results highlight the potential of the proposed microfluidic amperometric biosensor as a robust, real-time tool for biomedical lactate monitoring. Graphical Abstract
Background/Objectives: Preoperative discrimination of benign from malignant adnexal masses remains a major clinical challenge, and circulating microRNAs (miRNAs) are candidate non-invasive biomarkers. This exploratory, hypothesis-generating study—not a diagnostic validation study—evaluated serum hsa-miR-200c-3p as a candidate diagnostic biomarker for ovarian malignancy. Methods: Serum from 39 women with an adnexal mass and a surgical indication (20 benign, 19 malignant), all with histological confirmation, was analysed. Of 179 assayed miRNAs, 178 were tested for differential expression (miR-103a-3p as endogenous reference) using the Mann–Whitney U test with Benjamini–Hochberg false-discovery-rate (FDR) correction; hsa-miR-200c-3p, a pre-specified miR-200 family candidate, was evaluated by ROC analysis and compared with, and adjusted for, CA 125, HE4 and age. Results: The malignant group was substantially older and more frequently postmenopausal. Thirty-eight miRNAs were significant after FDR correction; hsa-miR-200c-3p was up-regulated in malignancy. In the complete-case analysis restricted to the 35 participants with a detectable marker (20 benign, 15 malignant), the AUC was 0.893 (95% CI 0.76–0.99); however, four high-grade serous carcinomas showed undetectable serum hsa-miR-200c-3p, and when these were included and imputed as low expression (all-case analysis, n = 39) the AUC fell to 0.705 (95% CI 0.51–0.88). hsa-miR-200c-3p did not demonstrate statistically superior performance to HE4 (AUC 0.93) or CA 125 (0.89), with overlapping confidence intervals; any incremental value beyond established markers and age was modest and exploratory. Conclusions: Serum hsa-miR-200c-3p is a preliminary candidate that requires prospective, age-matched, adequately powered validation with pre-specified assays and analysis plans.